Sign up for email updates


Back Pain & Osteoporosis
Coronary Heart Disease
Depression & Anxiety
Digestive Disorders
Heart Attack Prevention
Hypertension & Stroke
Lung Disorders
Nutrition & Weight Control
Prostate Disorders

Coronary Heart Disease

From the Current Issue

New Research
Clopidogrel Beats Aspirin for High-risk Patients

The antiplatelet drug clopidogrel (Plavix) appears better than aspirin at protecting some high-risk people from repeat heart attacks and strokes, according to a clinical trial.

Nearly 5,000 men and women with a history of heart attack, stroke, or peripheral arterial disease were randomly assigned to take either aspirin or clopidogrel every day for up to three years. Those who took clopidogrel were 15% less likely than those given aspirin to suffer another attack or die of cardiovascular disease over the next three years. When it came to combined risk of heart attack, stroke, or rehospitalization, clopidogrel again was superior to aspirin.

Aspirin is commonly prescribed to heart attack and stroke survivors to prevent future events. The new findings suggest that for these individuals, who are at particularly high risk for future events, the more expensive clopidogrel might be a better choice. By the end of the study, 20% of clopidogrel patients had died or suffered another heart attack or stroke, compared with 24% of those on aspirin.

The study did not test the combination of aspirin and clopidogrel.

Volume 35, page 528
February 2004



The Heart Bulletin is a quarterly publication that presents the latest information available to help you make informed decisions about your cardiac care.
Subscribe now


Buy now

Coronary Heart Disease

The Coronary Heart Disease White Paper from The Johns Hopkins White Papers series is an annual, in-depth report written by Johns Hopkins physicians.



    Contact us 
    © 2005 Medletter Associates, Inc.